National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- Adverse Drug Events (ADE) (2)
- Adverse Events (1)
- Anxiety (1)
- Behavioral Health (4)
- Children/Adolescents (1)
- Comparative Effectiveness (1)
- (-) Depression (5)
- Electronic Health Records (EHRs) (1)
- Health Information Technology (HIT) (2)
- Human Immunodeficiency Virus (HIV) (1)
- (-) Medication (5)
- Patient-Centered Outcomes Research (1)
- Patient Adherence/Compliance (1)
- Patient Safety (1)
- Rural Health (1)
- Telehealth (1)
- Women (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 5 of 5 Research Studies DisplayedWilkinson ST, Kiselycznyk C, Banasr M
Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression.
In this paper, the authors report serum brain-derived neurotrophic factor (BDNF) and plasma BDNF levels from a randomized controlled, adjunctive, sequential parallel comparison design trial of riluzole in major depressive disorder. The investigators noted that preliminary evidence suggested that lower baseline BDNF may be associated with better clinical response to riluzole.
AHRQ-funded; HS023000.
Citation: Wilkinson ST, Kiselycznyk C, Banasr M .
Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression.
J Affect Disord 2018 Dec 1;241:514-18. doi: 10.1016/j.jad.2018.08.075..
Keywords: Comparative Effectiveness, Depression, Medication, Patient-Centered Outcomes Research
Blumenthal KG, Li Y, Acker WW
Multiple drug intolerance syndrome and multiple drug allergy syndrome: epidemiology and associations with anxiety and depression.
In this study, the authors used electronic health record (EHR) data to describe prevalences of MDIS and MDAS and to examine associations with anxiety and depression. The investigators concluded that: 1.) while 6% of patients had MDIS, only 1% had MDAS; 2.) MDIS was associated with both anxiety and depression; 3.) patients with both anxiety and depression had an almost twofold increased odds of MDIS; 4.) MDAS was associated with a 40% increased odds of depression, but there was no significant association with anxiety.
AHRQ-funded; HS022728.
Citation: Blumenthal KG, Li Y, Acker WW .
Multiple drug intolerance syndrome and multiple drug allergy syndrome: epidemiology and associations with anxiety and depression.
Allergy 2018 Oct;73(10):2012-23. doi: 10.1111/all.13440..
Keywords: Adverse Drug Events (ADE), Adverse Events, Anxiety, Depression, Electronic Health Records (EHRs), Health Information Technology (HIT), Medication, Behavioral Health, Patient Safety
Katz RB, Toprak M, Wilkinson ST
Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: a letter to the editor.
This research letter describes the implications of concurrent use of ketamine and monoamine oxidase inhibitors (MAO-Is) in the treatment of depression. There have not been many studies examining this. A literature review was conducted and eight cases total were found. All but one did not experience cardiovascular adverse events and that on patient had comorbid cardiac history. While these results were promising, the authors stressed that it is still unknown if concurrent use is safe and further research is needed.
AHRQ-funded; HS023000.
Citation: Katz RB, Toprak M, Wilkinson ST .
Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: a letter to the editor.
Gen Hosp Psychiatry 2018 Sep - Oct;54:62-64. doi: 10.1016/j.genhosppsych.2018.05.007..
Keywords: Adverse Drug Events (ADE), Medication, Depression, Behavioral Health
Stringer KL, Azuero A, Ott C
Feasibility and acceptability of real-time antiretroviral adherence monitoring among depressed women living with HIV in the deep south of the US.
The purpose of this study was to present feasibility and acceptability data on the use of an electronic adherence monitor (EAM) among African American women in remote areas of the Southeastern United States with HIV and co-occurring depression. EAM and self-reported antiretroviral therapy (ART) adherence was monitored among 25 participants recruited at four HIV clinics in Alabama. Intra-class correlation showed a low degree of concordance between EAM and self-reported adherence. 83% of data collected via EAM was transmitted in real-time; the remainder was delayed though technological failures or was lost entirely. The authors conclude that EAM monitoring is feasible in a rural US setting but that technological difficulties may impede the device's usefulness for just-in-time adherence interventions.
AHRQ-funded; HS013852.
Citation: Stringer KL, Azuero A, Ott C .
Feasibility and acceptability of real-time antiretroviral adherence monitoring among depressed women living with HIV in the deep south of the US.
AIDS Behav 2018 May;23(5):1306-14. doi: 10.1007/s10461-018-2322-z..
Keywords: Depression, Health Information Technology (HIT), Human Immunodeficiency Virus (HIV), Medication, Behavioral Health, Patient Adherence/Compliance, Rural Health, Telehealth, Women
Joyce NR, Schuler MS, Hadland SE
Variation in the 12-month treatment trajectories of children and adolescents after a diagnosis of depression.
The purpose of this longitudinal cohort study was to characterize heterogeneity in 12-month trajectories of psychotherapy and antidepressant treatment in youths with depression. The investigators examined variation in baseline health, health care utilization, and health outcomes across classes with similar patterns of psychotherapy and antidepressant use.
AHRQ-funded; HS022998.
Citation: Joyce NR, Schuler MS, Hadland SE .
Variation in the 12-month treatment trajectories of children and adolescents after a diagnosis of depression.
JAMA Pediatr 2018 Jan;172(1):49-56. doi: 10.1001/jamapediatrics.2017.3808..
Keywords: Depression, Children/Adolescents, Behavioral Health, Medication